Wednesday, January 22, 2025 Clonal hematopoiesis of indeterminate potential and its association with treatment outcomes and adverse events in patients with solid tumorsA secondary analysis using CCTG CO26 and PA7 trials to investigate the incidence of CHIP in cfDNA from patients with solid tumors and explore its association with treatment outcomes and adverse events. Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. Krishnan T, Solar Vasconcelos JP, Titmuss E, Vanner RJ, Schaeffer DF, Karsan A, Lim H, Ho C, Gill S, Yip S, Chia SK, Kennecke HF, Jonker DJ, Chen EX, Renouf DJ, O’Callaghan CJ, Loree JM. Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors. Cancer Research Communications 5: 66-73. 2025. https://doi.org/10.1158/2767-9764.CRC-24-0522
